
Opinion|Videos|May 1, 2025
Genomic Assays in Breast Cancer: Key Differences, Clinical Utility, and Test Selection
Panelists discuss how they primarily use the 21-gene assay (Oncotype DX) for estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancers with minimal nodal disease due to its robust data from multiple trials, whereas other assays such as the Breast Cancer Index (BCI) are better for evaluating extended endocrine therapy benefits.
Advertisement
Comparing Available Genomic Assays
Main Discussion Topics:
- Differentiating factors between various genomic assays (Oncotype DX, MammaPrint, EndoPredict, Prosigna Breast Cancer Assay, BCI)
- Considerations for selecting the appropriate test for ER+/HER2– breast cancer
- Specific clinical scenarios where different assays may be preferred
Key Points for Physicians:
- The 21-gene assay (Oncotype DX) is preferred for ER+/HER2– breast cancers with negative or minimal nodal involvement due to robust supporting clinical trial data.
- BCI is valuable for assessing extended endocrine therapy benefit.
- The 70-gene assay (MammaPrint) may be useful for specific clinical trials and some HER2+ cases.
Notable Insights:
- Oncotype DX is supported by extensive clinical data (>80 trials/registries involving ~100,000 patients) and has been incorporated into staging systems.
- Test selection should be driven by the specific clinical question being addressed.
Clinical Significance: Although the 21-gene assay remains the most widely validated option for ER+/HER2– breast cancer, physicians should consider the specific clinical context and question when selecting between available genomic testing options.
Advertisement
Related to this article

The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia, granted priority review to elinzanetant for breast cancer hot flashes, and more.

The 2026 amendment adds 40 new recommendations, including active surveillance, office-based treatment, and chemoablation for select recurrent low-grade disease.

The FDA has approved pirtobrutinib for the treatment of adult patients with previously untreated CLL or SLL harboring no known 17p deletion.

By finding a way to attack the most important human oncogene, KRAS, the UCSF chemical biologist launched a new era in cancer treatment.

TRE-515 earned fast track status in combination with KRAS inhibitors for G12C-mutated NSCLC after anti–PD-(L)1 therapy and platinum-based chemotherapy.

An NDA for zipalertinib in EGFR exon 20 insertion–positive NSCLC is being supported by phase 3 REZILIENT3 data.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL
2
FDA Grants Fast Track Designation to TRE-515 Plus KRAS Inhibitors in Pretreated KRAS G12C+ NSCLC
3
NDA Submission Is Initiated for Zipalertinib Plus Chemotherapy in Frontline EGFR Exon 20 Insertion+ NSCLC
4
Oral Azacitidine and Cedazuridine Meets Primary Pharmacokinetic End Point in MDS and CMML
5

